Jul. 14 at 12:10 PM
Goldman Sachs y'day🏁
$STOK and said -- We initiate coverage of Stoke Therapeutics (STOK) with a Buy rating and a 12-month price target of
$44 (85%-weighted DCF value of
$43, 15%-weighted M&A value of
$49; M&A rank of 2).
$BIIB $PRAX DRUG HLUBF HLBBF HRMY IONS OVID UCBJY JAZZ
Here's what else Goldman Sachs had to say: https://x.com/Quantumup1/status/2077002438909784198?s=20
